to record information regarding their use of glucocorticoids during the “last 7 days” and during the “last 6 months”. We retrieved 132 questionnaires (of whom 6 were discarded as incomplete). All data was analyzed using SPSS Statistics v22.

**Results:** Of the 126 patients (mean age 74.9 ± 7.7 years, 59% were female). The mean duration of disease was 22.5 ± 19.1 months in patients with GCA and 32.9 ± 29.9 months in those with GCA and polymyalgia rheumatica (PMR). The mean daily number of medications taken was 9.2 ± 5.2 (range: 1 - 30); the mean number of types of daily tablets taken was 5.0 ± 2.1 (range: 1 - 10). The mean daily number of glucocorticoid tablets taken was 3.2 ± 2.6 (range: 0 - 12); with a mean daily dose of 11.1 ± 10.3 mg (range: 0 - 60 mg). Overall, in the last 7 days, 22% and in last 6 months, 40% of patients were not following their original recommended steroid regimens (Table 1). The total mean glucocorticoid dose in the “last 7 days” group (n=81) was 77.8 ± 70.1 mg/week (11.1 ± 10.1 mg/day) whilst the total mean glucocorticoid dose in the “last 6 months” group (n=45) was 178.2 ± 1543.3 mg/6 month (9.9 ± 8.6 mg/day). Most respondents stated their glucocorticoid non-adherence was due to medical advice; other reasons included forgetting, fear of side effects, or confusion about diem preparations of prescribed glucocorticoids. The presence of PMR did not influence glucocorticoid adherence.

**Table 1. Glucocorticoid used compared to original regimen in GCA**

<table>
<thead>
<tr>
<th></th>
<th>Last 7 days (%)</th>
<th>Last 6 months (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Higher than prescribed</td>
<td>16</td>
<td>22</td>
</tr>
<tr>
<td>Lower than prescribed</td>
<td>6</td>
<td>18</td>
</tr>
<tr>
<td>Same as prescribed</td>
<td>78</td>
<td>60</td>
</tr>
</tbody>
</table>

**Conclusion:** There is significant variation in the use of glucocorticoids compared to the original starting regimen in patients with GCA, with or without PMR. However, the amount of the discrepancy is small. The commonest reason for non-adherence was medical advice received from either primary or secondary care.

**References:**


**Disclosure of Interests:** HAI RUL HADI ARIFF: None declared, Abd Awaisat. None declared. JACK ARNOLD: None declared, Hudaifa Al Ani: None declared, Lorraine O’Neill: None declared, Mar Pujades Rodriguez: None declared, Raasheid Lugmani Grant/research support from: Arthritis UK, the Medical Research Council, the University of California San Francisco/Oxford Invention Fund, the Canadian Institutes of Health Research, The Vasculitis Foundation, GSK, Consultant of: GSK, Medpace, Medimmune, Roche

DOI: 10.1136/annrheumdis-2020-eular.283
Results: 151 patients participated: 50 with RA (90% women, mean age 55.12 ± 13.64 years), 51 with AS (51% women, 52.59 ± 12.15 years) and 50 patients with SLE (96% women, mean age 47.14 ± 11.3 years). The most frequent comorbidities were: visual impairment, anxiety and depression (table 1). These results present a greater tendency to depression and anxiety patients of SLE. No significant differences were observed in most of the social questionnaires analyzed between groups (table 2), except in a worse mobility in patients with RA and AD compared to SLE (p = 0.017). About half of the patients in all groups had depression (43%) and reduced mobility (83.6%). All groups are satisfied with their social role 128 (85.3%), have the capacity to participate in social activities 140 (94%) and feel accompanied 147 (97.4%). On the contrary, the social isolation figure is 42 (28%). Social isolation implies an affecting of the serious social role in patients who claim to be accompanied, so it is not secondary to loneliness or lack of family support.

In the multivariate analysis it was observed that the independent variables that were associated with the ability to participate in social activities in satisfaction with social relations (β = 0.349 [p < 0.001]), mobility (β = 0.309 [p < 0.001]), depression (β = 0.186 [p < 0.01]) and social isolation (β = 0.195 [p = 0.001]). This model would explain 32% of the variability in the ability to participate in social activities. (R2 = 0.32).

Conclusion: The predictors of the ability to participate in social activities in patients with RA, AD and SLE were: depression, mobility deficit, social isolation and satisfaction with social activities. Patients with RA, AD and SLE present similar data, so there are no differences due to pathologies in the social dynamics, highlighting that they have a good social support and despite this there is social isolation being able to be associated with the deficit in mobility and high rates of depression.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2020-eular.845

SAT0623-HPR THE LIVED EXPERIENCES OF COGNITIVE Dysfunction IN ADULTS WITH FIBROMYALgia: A QUALITATIVE SYSTEMATIC REVIEW

S. Dahram1, J. Lewis2,3, E. Dures4,5, F. Cramp3,1
1Royal United Hospitals Bath NHS Foundation Trust, Bath, United Kingdom; 2University of the West of England, Department of Allied Health Professions, Bristol, United Kingdom; 3Royal United Hospitals Bath NHS Foundation Trust, Complex Regional Pain Syndrome Service, Bath, United Kingdom; 4University of the West of England, Centre for Health and Clinical Research, Bristol, United Kingdom; 5Bristol Royal Infirmary, Department of Nursing and Midwifery, Bristol, United Kingdom

Background: Adults with fibromyalgia frequently report symptoms of cognitive dysfunction, often referred to as fibro fog. However primary research exploring cognitive dysfunction in the lives of adults with fibromyalgia is very limited (Kratz and Katz, 2015).

Objectives: The aim of this review was to (i) synthesise the qualitative literature on the lived experiences of cognitive dysfunction in adults with fibromyalgia, (ii) develop common themes through thematic analysis and (iii) identify knowledge gaps to inform future research and clinical practice in this area.

Methods: Seven electronic databases (MEDLINE, Embase, CINAHL, PsycINFO, Amed, Scopus and OpenGrey), reference lists of key articles and two high impact qualitative journals were searched from 1990 to November 2018. Articles were eligible for inclusion if they reported primary qualitative data exploring the experiences of cognitive dysfunction in adults with fibromyalgia. Included studies were appraised using the Critical Appraisal Skills Programme (CASP) qualitative checklist and extracted data analysed using narrative synthesis. SD conducted a critical appraisal of the extracted data on all included studies. FC, JL, and ED reviewed five papers each. All papers were reviewed by two co-authors. Of the 1413 records identified, 15 studies were selected for inclusion.

Results: These studies included 208 women and 22 men with fibromyalgia, aged 18 to 72 years and representing seven different countries. Duration of diagnosis was four months to 34 years. Fourteen studies used interviews and one used focus groups. Most of the focus groups included small numbers of participants, and included studies focussed exclusively on cognitive dysfunction in adults with fibromyalgia. Three studies identified themes specific to cognitive dysfunction and fibromyalgia symptoms. The remaining 12 studies presented relevant data intertwined with the overall lived experiences of fibromyalgia.

Cognitive dysfunction, as a part of fibromyalgia, was often unpredictable. Problems with memory and concentration that were most commonly reported were emotionally distressing and affected functional and vocational activities. Participants found communication difficult, with a negative impact on work, leisure and social activities. Stress, fear and worry around perceived cognitive changes were commonly expressed. Lost employment or changed work roles and relationships, due to cognitive difficulties, had negative impacts for many participants. The terms cognitive dysfunction and fibro fog were used interchangeably within the studies, but lacked common definition. This introduced uncertainty around whether participants and authors were describing the same phenomenon.

Conclusion: Adults with fibromyalgia experience unpredictable and emotionally impactful difficulties related to cognitive dysfunction. Functional impact was broad-reaching, particularly around work ability and lost employment opportunities. It is unclear how cognitive symptoms in fibromyalgia related to co-morbid symptoms such as pain, fatigue and poor sleep. Further research focusing on the full impact of cognitive dysfunction on the lives of adults with fibromyalgia is recommended to inform clinical practice. Research to establish clarity of definition of the terms cognitive dysfunction and fibro fog within fibromyalgia is highly recommended.

References:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2020-eular.5260

SAT0622-HPR SAFETY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN BIOLOGICAL TREATMENT OVER 65 YEARS OF AGE

A. Crespo Golmar1, C. Moriano1, I. González Fernández1, X. E. Larco Rojas1, A. López Robles1, T. Pérez Sandoval1. 1Service, Rheumatology, Leon, Spain

Background: A bias has been described with the lowest prescription of biological treatments (bDMARD) in patients with rheumatoid arthritis (RA) in the elderly, despite presenting activity rates comparable to young population and higher risk of functional disability. This could be due to concerns about co-morbidities and polypharmacy1.

Objectives: 1) To define the characteristics of patients with RA ≥65 years and bDMARD to follow up in the Day Hospital of University Assistance Complex of León during the last year. 2) To record the incidence rate (IT) and ratio of incidence of (RD) of infections, neoplasms and cardiovascular events (CD) during the course of your therapy.

Methods: Observational, retrospective study of patients diagnosed with RA according to ACR 1987 and/or ACR 2010 criteria in intrabional biological treatment during 2019 with ≥65.

Results: 40 patients with an average age of diagnosis of 55.9±15.78 years were included, 67.5 % of them were women. The average duration of the disease was 17.68±13.15 years. 40% had a history of smoking, 35% hypertension, 20% dyslipemia and 20% diabetes mellitus. A 97.5% were positive FRRA, 57% positive ACPR, 37.5% nodular and 65% erosive. As for pre-treatment, 70% had been with conventional (cDMARD) ≥2DMARD (Methotrexate (MTX) (92.5%) and Leflunomide (60%)). The incidence rate of infections was 1.15%, and neoplasms and CD were 0.75% per-person-years. The age at the beginning of the first bDMARD was 67.45 ± 8 years, the second (n=20) 67.98±6.4 and the third (n=7) 71.79±7.49. The first biological was a 52.5% anti-TNF, 5% anti-CTLA4, 30% anti-CD20 and 12.5% antiIL6 (25% monotherapy and combined with MTX 57.5%). The second was 30% anti-TNF, 25% antiCTLA4, 15% antiIL6 and 30% antiCD20 (50% in monotherapy and 40% methotrexate); with the third anti-TNF 42.85%, antiCTLA4 14.29%, antiIL6 14.29% and antiCD20 28.57% (42.86% in monotherapy and 42.46 with methotrexate). The mean doses of prednisone were 6.08±6.82, 4.38±7.21 and 6.95±5.94 mg/day respectively. The IT of bDMARD was 6.08±6.82, 4.38±7.21 and 6.95±5.94 mg/da y respectively. The IT of bDMARD compared to ≥2 cDMARD and required medium-high doses of prednisone.